United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
302.41
-2.40 (-0.79%)
Aug 6, 2025, 4:00 PM - Market closed

Company Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.

It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.

United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation
United Therapeutics logo
CountryUnited States
Founded1996
IPO DateJun 17, 1999
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees1,305
CEOMartine Rothblatt

Contact Details

Address:
1000 Spring Street
Silver Spring, Maryland 20910
United States
Phone301 608 9292
Websiteunither.com

Stock Details

Ticker SymbolUTHR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001082554
CUSIP Number91307C102
ISIN NumberUS91307C1027
Employer ID52-1984749
SIC Code2834

Key Executives

NamePosition
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.Founder, Chairman and Chief Executive Officer
Michael I. BenkowitzPresident and Chief Operating Officer
James C. EdgemondChief Financial Officer and Treasurer
Paul A. Mahon J.D.Executive Vice President, General Counsel and Corporate Secretary
Dewey Steadman C.F.A.Head of Investor Relations
Holly HobsonAssociate Vice President of Human Resources
Kevin T. GraySenior Vice President of Strategic Operations and Logistics
Patrick PoissonExecutive Vice President of Technical Operations
Dr. Leigh PetersonExecutive Vice President of Product Development and Xenotransplantation
Gil GoldenSenior Vice President and Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Aug 1, 20258-KCurrent Report
Jul 30, 2025S-8Securities to be offered to employees in employee benefit plans
Jul 30, 20258-KCurrent Report
Jul 30, 202510-QQuarterly Report
Jul 24, 2025144Filing
Jul 10, 2025144Filing
Jun 27, 20258-KCurrent Report
Jun 26, 2025144Filing
Jun 24, 2025144Filing
Jun 24, 2025144Filing